Europe Advanced Wound Care Market

Europe Advanced Wound Care Market Size (2024 to 2032)

The size of the European advanced wound care market is estimated to be worth USD 4.60 billion by 2032 and USD 3.2 billion in 2024, growing at a CAGR of 4.63% during the forecast period.

The increasing number of surgical procedures for chronic diseases in the European region is driving the European advanced wound care market growth. The increasing number of surgeries in Europe is due to the availability of affordable and accessible treatment options in Europe, which is further leading to the incidence of surgery wounds and infections with an increase in chronic diseases. In addition, sophisticated treatments such as NPWT are contributing to the growth of the advanced wound care market in Europe. Most of the surgical techniques are developing wound infections, severe bleeding, and tissue damage, which need wound care. According to an article published in 2021, German Heart Surgery Report: German Society for Thoracic and Cardiovascular Surgery Department annual registry update stated 29,444 isolated coronary artery bypass grafting procedures, 35,470 isolated heart valve procedures, and 858 assist device implantations were registered in Germany. Using advanced wound care products with antimicrobial agents will help speed the healing process by reducing bacterial contamination and infection.

The growth of the European advanced wound care market is further driven by the growing public awareness of its advantages. A research paper published in 2021, "Wound Antiseptics and European Guidelines for Antiseptic Application in Wound Treatment," stated that chronic wound infections afflict around 1.5% of people, and issues with wound healing are high. 

Technological advancements and the launch of novel products are further supporting the growth of the European advanced wound care market. The introduction of novel compounds for absorption, hydration, and antibacterial activity, along with research and development in advanced wound care, prompted the market share and is estimated to drive the European advanced wound care market in the forecast period. This helped convert simple dressing methods to advanced ones and increased demand for products with pharmaceutical active ingredients. 

The increasing prevalence of diabetes and associated chronic diseases is expected to significantly impact the advanced wound care market, propelling it during the forecast period. The increasing government initiatives for providing better-advanced wound care in emerging areas are expected to create lucrative opportunities for market growth. The new launches by manufacturers are expected to promote opportunities for market expansion during the forecast period.

On the other hand, the high cost of advanced wound care products is hampering the growth of the European advanced wound care market. The high price of chronic wound treatment products also hinders the market in emerging areas with low income. Due to cost variation, patients and physicians prefer inexpensive products. The reimbursement issues for the new technologies are expected to impede market growth. Adopting advanced wound care in less developed areas is challenging for market expansion. Due to cost and old beliefs, people in low-income areas prefer inexpensive treatment, and even medical professionals prescribe it.

This research report on the European advanced wound care market has been segmented and sub-segmented into the following categories:

Europe Advanced Wound Care Market Analysis By Type

• Dressings
• Therapy Devices
• Active wound care

Based on type, the dressing segment is expected to register a leading share of the European advanced wound care market during the forecast period.

Europe Advanced Wound Care Market Analysis By Application

• Skin Ulcers
• Surgical Wounds
• Burn Wounds

The skin ulcers segment is anticipated to dominate the other segments in the European market during the forecast period.

Europe Advanced Wound Care Market Analysis By End-User

• In-patient services
• Out-patient services

Europe Advanced Wound Care Market Analysis By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

After North America, the European region was the leading segment by dominating the market due to the progressive and continuous product innovations and market launches by the market players. These innovations are expected to augment further in the market trend. Germany is expected to dominate the European advanced wound care market with the highest market share due to the country's investments in the dressing segment, and diabetic ulcers are more prevalent in this region. Germany's Covestro, in 2021, initiated a European Union project for research in the recycling of polyurethane foams. This project will save EUR 150 million per year in polyurethane incineration costs. These initiatives reduce raw material costs and influence market expansion during the forecast period. 

The increase in geriatric patients with the availability of reimbursement profiles for the dressing segment is enhancing the UK advanced wound care market by ranking it second in the European market. The increasing number of diabetic cases with surgeries needing advanced wound care was prompting the market growth in the U.K. France was expected to dominate in the market share during the forecast period due to its increased chronic wound cases in the region. The new launches are another factor influencing the market growth in France. Accel-Heal is a product launched in France in 202 that facilitates the broader adoption of electrical stimulation wound therapy. It suits dressing regimens and can be applied to all chronic wounds, including diabetic foot ulcers. Italy and Spain are expected to have decent growth in the forecast period.

KEY MARKET PARTICIPANTS

A few of the notable companies operating in Europe advanced wound care market are Acelity L.P., Inc., Smith and Nephew Plc., Mölnlycke Health Care, ConvaTec, Coloplast Corp., 3M Healthcare, Medtronic, Integra Lifesciences Corporation, and Organogenesis Inc.